AMD not affected by vitreomacular adhesion

Article

Vitreomacular adhesion (VMA) does not affect the development of exudative age-related macula degeneration.

Vitreomacular adhesion (VMA) does not affect the development of exudative age-related macula degeneration, according to the results of a 4-year longitudinal study in Retina.

The prospective, longitudinal investigation, led by Dr Sebastian Waldstein, Department of Ophthalmology, Medical University of Vienna, Austria, included 49 patients with AMD who underwent optical coherence tomography (OCT) and fluorescein angiography (FA) every three months for four years.

Time-domain and spectral-domain OCT were used to assess vitreomacula adhesion. OCT and FA were also used to determine development of choroidal neovascularization (CNV). CNV incidences were compared in all patients, through the presence or absence of VMA.

Of the patients studied, nine presented with VMA at baseline and 18 patients experienced exudative changes during the observation period. Development of CNV was present in 33% of patients with pre-existing VMA and 38% in patients without VMA.

In VMA patients the mean interval from baseline to disease progression was 20 ± 19 months and 22 ± 13 months in patients without VMA. Rate of CNV development and time to disease progression were not significantly different between the groups.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.